Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination.

Chapple AG, Thall PF.

Pharm Stat. 2018 Aug 15. doi: 10.1002/pst.1891. [Epub ahead of print]

PMID:
30112806
2.

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.

Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH.

Leuk Lymphoma. 2018 Jul 22:1-11. doi: 10.1080/10428194.2018.1485908. [Epub ahead of print]

PMID:
30032678
3.

Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation.

Davies JK, Brennan LL, Wingard JR, Cogle CR, Kapoor N, Shah AJ, Dey BR, Spitzer TR, de Lima M, Cooper LJ, Thall PF, Champlin RE, Nadler LM, Guinan EC.

Clin Cancer Res. 2018 Sep 1;24(17):4098-4109. doi: 10.1158/1078-0432.CCR-18-0449. Epub 2018 May 16.

PMID:
29769208
4.

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.

Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1602-1609. doi: 10.1016/j.bbmt.2018.02.020. Epub 2018 Mar 2.

PMID:
29501779
5.

A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups.

Murray TA, Yuan Y, Thall PF, Elizondo JH, Hofstetter WL.

Biometrics. 2018 Sep;74(3):1095-1103. doi: 10.1111/biom.12842. Epub 2018 Jan 22.

6.

Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding.

Yan F, Thall PF, Lu KH, Gilbert MR, Yuan Y.

Ann Oncol. 2018 Mar 1;29(3):694-699. doi: 10.1093/annonc/mdx795.

PMID:
29267863
7.

Clinical Trial Design as a Decision Problem.

Müller P, Xu Y, Thall PF.

Appl Stoch Models Bus Ind. 2017 May-Jun;33(3):296-301. doi: 10.1002/asmb.2222. Epub 2017 Jan 13.

8.

Bayesian variable selection for a semi-competing risks model with three hazard functions.

Chapple AG, Vannucci M, Thall PF, Lin S.

Comput Stat Data Anal. 2017 Aug;112:170-185. doi: 10.1016/j.csda.2017.03.002. Epub 2017 Mar 22.

9.

A simulation study of outcome adaptive randomization in multi-arm clinical trials.

Wathen JK, Thall PF.

Clin Trials. 2017 Oct;14(5):432-440. doi: 10.1177/1740774517692302. Epub 2017 Feb 1.

10.

A Decision-Theoretic Comparison of Treatments to Resolve Air Leaks After Lung Surgery Based on Nonparametric Modeling.

Xu Y, Thall PF, Müller P, Mehran RJ.

Bayesian Anal. 2017;12(3):639-652. doi: 10.1214/16-BA1016. Epub 2016 Jul 26.

11.

Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer.

Murray TA, Thall PF, Yuan Y, McAvoy S, Gomez DR.

J Am Stat Assoc. 2017;112:11-23. doi: 10.1080/01621459.2016.1176926. Epub 2017 May 3.

12.

Bayesian treatment comparison using parametric mixture priors computed from elicited histograms.

Thall PF, Ursino M, Baudouin V, Alberti C, Zohar S.

Stat Methods Med Res. 2017 Jan 1:962280217726803. doi: 10.1177/0962280217726803. [Epub ahead of print]

13.

Bayesian nonparametric statistics: A new toolkit for discovery in cancer research.

Thall PF, Mueller P, Xu Y, Guindani M.

Pharm Stat. 2017 Nov;16(6):414-423. doi: 10.1002/pst.1819. Epub 2017 Jul 4.

PMID:
28677272
14.

Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer.

Lin SH, Merrell KW, Shen J, Verma V, Correa AM, Wang L, Thall PF, Bhooshan N, James SE, Haddock MG, Suntharalingam M, Mehta MP, Liao Z, Cox JD, Komaki R, Mehran RJ, Chuong MD, Hallemeier CL.

Radiother Oncol. 2017 Jun;123(3):376-381. doi: 10.1016/j.radonc.2017.04.013. Epub 2017 Apr 25.

PMID:
28455153
15.

Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal Outcomes.

Thall PF, Nguyen HQ, Zinner RG.

J R Stat Soc Ser C Appl Stat. 2017 Jan;66(1):201-224. doi: 10.1111/rssc.12162. Epub 2016 Jun 11.

16.

A simulation study of methods for selecting subgroup-specific doses in phase 1 trials.

Morita S, Thall PF, Takeda K.

Pharm Stat. 2017 Mar;16(2):143-156. doi: 10.1002/pst.1797. Epub 2017 Jan 23.

17.

Bayesian Nonparametric Estimation for Dynamic Treatment Regimes with Sequential Transition Times.

Xu Y, Müller P, Wahed AS, Thall PF.

J Am Stat Assoc. 2016;111(515):921-935. doi: 10.1080/01621459.2015.1086353. Epub 2016 Oct 18.

18.

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.

Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE.

Bone Marrow Transplant. 2017 Apr;52(4):580-587. doi: 10.1038/bmt.2016.322. Epub 2016 Dec 19.

19.

Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer.

He L, Chapple A, Liao Z, Komaki R, Thall PF, Lin SH.

Radiother Oncol. 2016 Oct;121(1):70-74. doi: 10.1016/j.radonc.2016.08.005. Epub 2016 Aug 22.

20.

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ.

Leukemia. 2017 Mar;31(3):697-704. doi: 10.1038/leu.2016.254. Epub 2016 Sep 22.

21.

Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.

Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1792-1800. doi: 10.1016/j.bbmt.2016.06.023. Epub 2016 Jul 1.

22.

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS.

Cancer. 2016 Sep 1;122(17):2680-8. doi: 10.1002/cncr.30100. Epub 2016 May 20.

23.

Utility-based designs for randomized comparative trials with categorical outcomes.

Murray TA, Thall PF, Yuan Y.

Stat Med. 2016 Oct 30;35(24):4285-4305. doi: 10.1002/sim.6989. Epub 2016 May 18.

24.

Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival.

Hobbs BP, Thall PF, Lin SH.

J R Stat Soc Ser C Appl Stat. 2016 Feb;65(2):273-297. Epub 2015 Oct 26.

25.

A decision-theoretic phase I-II design for ordinal outcomes in two cycles.

Lee J, Thall PF, Ji Y, Müller P.

Biostatistics. 2016 Apr;17(2):304-19. doi: 10.1093/biostatistics/kxv045. Epub 2015 Nov 9.

26.

Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity.

Lee J, Thall PF, Ji Y, Müller P.

J Am Stat Assoc. 2015 Jun 1;110(510):711-722.

27.

Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial.

Sandberg DI, Rytting M, Zaky W, Kerr M, Ketonen L, Kundu U, Moore BD, Yang G, Hou P, Sitton C, Cooper LJ, Gopalakrishnan V, Lee DA, Thall PF, Khatua S.

J Neurooncol. 2015 Oct;125(1):133-41. doi: 10.1007/s11060-015-1878-y. Epub 2015 Aug 9.

28.

Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma.

Tseng WW, Zhou S, To CA, Thall PF, Lazar AJ, Pollock RE, Lin PP, Cormier JN, Lewis VO, Feig BW, Hunt KK, Ballo MT, Patel S, Pisters PW.

Cancer. 2015 Oct 15;121(20):3659-67. doi: 10.1002/cncr.29544. Epub 2015 Jul 15.

29.

Optimization of multi-stage dynamic treatment regimes utilizing accumulated data.

Huang X, Choi S, Wang L, Thall PF.

Stat Med. 2015 Nov 20;34(26):3424-43. doi: 10.1002/sim.6558. Epub 2015 Jun 21.

30.

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.

Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1914-20. doi: 10.1016/j.bbmt.2015.06.003. Epub 2015 Jun 11.

31.

Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation.

Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, López AA, Yap DY, Popat U, Rondon G, Lichtiger B, Aung F, Afshar-Kharghan V, Ma Q, Fernández-Viña M, Champlin RE, Cao K.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1392-8. doi: 10.1016/j.bbmt.2015.05.001. Epub 2015 May 15.

32.

Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials.

Thall P, Fox P, Wathen J.

Ann Oncol. 2015 Aug;26(8):1621-8. doi: 10.1093/annonc/mdv238. Epub 2015 May 15.

33.

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation.

Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin B, Wang RY, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Andreeff M, Champlin R.

Bone Marrow Transplant. 2015 Jul;50(7):939-946. doi: 10.1038/bmt.2015.58. Epub 2015 Apr 13.

34.

Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.

Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH.

Leukemia. 2015 Sep;29(9):1945-8. doi: 10.1038/leu.2015.54. Epub 2015 Feb 27. No abstract available.

35.

Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas.

Wang J, Milton DR, He L, Komaki R, Liao Z, Crane CH, Minsky BD, Thall PF, Lin SH.

J Thorac Oncol. 2015 Mar;10(3):518-26. doi: 10.1097/JTO.0000000000000457.

36.

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.

Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H.

Haematologica. 2015 Jul;100(7):927-34. doi: 10.3324/haematol.2014.118455. Epub 2015 Feb 14.

37.

Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes.

Jin IH, Liu S, Thall PF, Yuan Y.

J Am Stat Assoc. 2014;109(506):525-536.

38.

Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome.

Thall PF, Nguyen HQ, Zohar S, Maton P.

J Am Stat Assoc. 2014 Sep 1;109(507):931-943.

39.

Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcome.

Graziani R, Guindani M, Thall PF.

Biometrics. 2015 Mar;71(1):188-197. doi: 10.1111/biom.12250. Epub 2014 Oct 15.

40.

Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.

Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik L.

J Clin Oncol. 2014 Nov 1;32(31):3497-505. doi: 10.1200/JCO.2013.54.0625. Epub 2014 Sep 29.

41.

Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding.

Thall PF, Herrick RC, Nguyen HQ, Venier JJ, Norris JC.

Clin Trials. 2014 Dec;11(6):657-66. doi: 10.1177/1740774514547397. Epub 2014 Sep 1.

42.
43.

Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time.

Tang X, Alatrash G, Ning J, Jakher H, Stafford P, Zope M, Shpall EJ, Jones RB, Champlin RE, Thall PF, Andersson BS.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1139-44. doi: 10.1016/j.bbmt.2014.04.003. Epub 2014 Apr 13.

44.
45.

A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.

Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG.

Ann Oncol. 2013 Nov;24(11):2844-9. doi: 10.1093/annonc/mdt339. Epub 2013 Aug 23.

46.

Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes.

Thall PF, Nguyen HQ, Braun TM, Qazilbash MH.

Biometrics. 2013 Sep;69(3):673-82. doi: 10.1111/biom.12065. Epub 2013 Aug 19.

47.

A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.

Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1453-8. doi: 10.1016/j.bbmt.2013.07.008. Epub 2013 Jul 17.

48.

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ.

Clin Cancer Res. 2013 Jul 1;19(13):3621-30. doi: 10.1158/1078-0432.CCR-12-3791. Epub 2013 May 6.

49.

Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor size.

David E, Thall PF, Kalhor N, Hofstetter WL, Rice DC, Roth JA, Swisher SG, Walsh GL, Vaporciyan AA, Wei C, Mehran RJ.

Ann Thorac Surg. 2013 Jun;95(6):1872-7; discussion 1877. doi: 10.1016/j.athoracsur.2013.03.085. Epub 2013 May 2.

50.

Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience.

Yilmaz M, Chemaly RF, Han XY, Thall PF, Fox PS, Tarrand JJ, De Lima MJ, Hosing CM, Popat UR, Shpall E, Champlin RE, Qazilbash MH.

Bone Marrow Transplant. 2013 Sep;48(9):1218-23. doi: 10.1038/bmt.2013.33. Epub 2013 Mar 18.

Supplemental Content

Support Center